These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 16344498

  • 1. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Yanaba K, Komura K, Kodera M, Matsushita T, Hasegawa M, Takehara K, Sato S.
    Ann Rheum Dis; 2006 Jan; 65(1):124-6. PubMed ID: 16344498
    [Abstract] [Full Text] [Related]

  • 2. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S, Komura K, Hasegawa M, Fujimoto M, Takehara K.
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.
    Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP.
    Arthritis Rheum; 2003 Jul; 48(7):1979-91. PubMed ID: 12847692
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
    Hara T, Ogawa F, Yanaba K, Iwata Y, Muroi E, Komura K, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S.
    J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
    [Abstract] [Full Text] [Related]

  • 8. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
    Yanaba K, Muroi E, Yoshizaki A, Hara T, Ogawa F, Shimizu K, Yozaki M, Hasegawa M, Fujimoto M, Takehara K, Sato S.
    J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
    [Abstract] [Full Text] [Related]

  • 9. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y, Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Tamaki K.
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [Abstract] [Full Text] [Related]

  • 10. Increased serum interleukin 23 in patients with systemic sclerosis.
    Komura K, Fujimoto M, Hasegawa M, Ogawa F, Hara T, Muroi E, Takehara K, Sato S.
    J Rheumatol; 2008 Jan; 35(1):120-5. PubMed ID: 18085738
    [Abstract] [Full Text] [Related]

  • 11. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis.
    Hasegawa M, Fujimoto M, Kikuchi K, Takehara K.
    J Rheumatol; 1997 Apr; 24(4):663-5. PubMed ID: 9101498
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
    Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S.
    J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
    [Abstract] [Full Text] [Related]

  • 13. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S.
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis.
    Asano Y, Ihn H, Kubo M, Jinnin M, Mimura Y, Ashida R, Tamaki K.
    Rheumatology (Oxford); 2006 Mar; 45(3):303-7. PubMed ID: 16278285
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y, Yoshizaki A, Ogawa F, Komura K, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Takehara K, Sato S.
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [Abstract] [Full Text] [Related]

  • 17. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K.
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [Abstract] [Full Text] [Related]

  • 18. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis.
    Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S.
    J Rheumatol; 2011 Oct; 38(10):2193-7. PubMed ID: 21807780
    [Abstract] [Full Text] [Related]

  • 19. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
    Hamaguchi Y, Fujimoto M, Matsushita T, Hasegawa M, Takehara K, Sato S.
    J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, Tamaki K.
    J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.